124 related articles for article (PubMed ID: 12690615)
1. CYP3A4: a potential prostate cancer risk factor for high-risk groups.
Zeigler-Johnson C
Clin J Oncol Nurs; 2001; 5(4):153-4. PubMed ID: 12690615
[TBL] [Abstract][Full Text] [Related]
2. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
Paris PL; Kupelian PA; Hall JM; Williams TL; Levin H; Klein EA; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):901-5. PubMed ID: 10548319
[TBL] [Abstract][Full Text] [Related]
3. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Keshava C; McCanlies EC; Weston A
Am J Epidemiol; 2004 Nov; 160(9):825-41. PubMed ID: 15496535
[TBL] [Abstract][Full Text] [Related]
4. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Rebbeck TR; Jaffe JM; Walker AH; Wein AJ; Malkowicz SB
J Natl Cancer Inst; 1998 Aug; 90(16):1225-9. PubMed ID: 9719084
[TBL] [Abstract][Full Text] [Related]
5. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.
Walker AH; Jaffe JM; Gunasegaram S; Cummings SA; Huang CS; Chern HD; Olopade OI; Weber BL; Rebbeck TR
Hum Mutat; 1998; 12(4):289. PubMed ID: 10660343
[TBL] [Abstract][Full Text] [Related]
7. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
[TBL] [Abstract][Full Text] [Related]
8. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?
Kittles RA; Chen W; Panguluri RK; Ahaghotu C; Jackson A; Adebamowo CA; Griffin R; Williams T; Ukoli F; Adams-Campbell L; Kwagyan J; Isaacs W; Freeman V; Dunston GM
Hum Genet; 2002 Jun; 110(6):553-60. PubMed ID: 12107441
[TBL] [Abstract][Full Text] [Related]
9. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy.
Powell IJ; Zhou J; Sun Y; Sakr WA; Patel NP; Heilbrun LK; Everson RB
J Urol; 2004 Nov; 172(5 Pt 1):1848-52. PubMed ID: 15540736
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Sarma AV; Dunn RL; Lange LA; Ray A; Wang Y; Lange EM; Cooney KA
Prostate; 2008 Feb; 68(3):296-305. PubMed ID: 18163429
[TBL] [Abstract][Full Text] [Related]
11. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans.
Kittles RA; Panguluri RK; Chen W; Massac A; Ahaghotu C; Jackson A; Ukoli F; Adams-Campbell L; Isaacs W; Dunston GM
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):943-7. PubMed ID: 11535545
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome and sulfotransferase gene variation in north African populations.
Fernández-Santander A; Novillo A; Gaibar M; Romero-Lorca A; Moral P; Sánchez-Cuenca D; Amir N; Chaabani H; Harich N; Esteban ME
Pharmacogenomics; 2016 Aug; 17(13):1415-23. PubMed ID: 27471773
[TBL] [Abstract][Full Text] [Related]
13. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.
Tayeb MT; Clark C; Sharp L; Haites NE; Rooney PH; Murray GI; Payne SN; McLeod HL
Oncol Rep; 2002; 9(3):653-5. PubMed ID: 11956645
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
15. Relationship of early-onset baldness to prostate cancer in African-American men.
Zeigler-Johnson C; Morales KH; Spangler E; Chang BL; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):589-96. PubMed ID: 23532004
[TBL] [Abstract][Full Text] [Related]
16. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
17. Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention.
Sakr WA
Eur Urol; 1999; 35(5-6):474-8. PubMed ID: 10325508
[TBL] [Abstract][Full Text] [Related]
18. Germ-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men.
Miller DC; Zheng SL; Dunn RL; Sarma AV; Montie JE; Lange EM; Meyers DA; Xu J; Cooney KA
Cancer Res; 2003 Jul; 63(13):3486-9. PubMed ID: 12839931
[TBL] [Abstract][Full Text] [Related]
19. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls.
Tang YM; Green BL; Chen GF; Thompson PA; Lang NP; Shinde A; Lin DX; Tan W; Lyn-Cook BD; Hammons GJ; Kadlubar FF
Pharmacogenetics; 2000 Dec; 10(9):761-6. PubMed ID: 11221602
[TBL] [Abstract][Full Text] [Related]
20. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
